Malawi Trial Shows New Typhoid Vaccine Effective in Children

Malawi plans a nationwide rollout of the newest typhoid vaccine after a two-year study, the first in Africa, found it safe and effective in children as young as 9 months. Previously available vaccines were found not effective in children younger than 2 years and even then only provided short-term protection.

Typhoid is an increasing public health threat in Malawi and across sub-Saharan Africa with an estimated 1.2 million cases and 19,000 deaths each year.

Typhoid is a treatable bacterial infection that has become a serious threat in many low- and middle-income countries.

In Malawi, the study on the efficacy of the Typhoid Conjugate Vaccine or TCV involved about 28,000 children aged between 9 months and 15 years from three townships in the commercial capital, Blantyre.

The University of Maryland School of Medicine’s Center for Vaccine Development and Global Health, the Blantyre Malaria Project, and the Malawi-Liverpool-Wellcome Trust conducted the study.

Professor Melita Gordon, principal investigator for the study at the Malawi-Liverpool Wellcome Trust, says the results, released this week, show an efficacy rate of more than 80% in protecting children against the disease.

“The previous vaccines were only 50% effective, and they were never even tested very well in the very youngest children. They were never even usable in the youngest children. So, the fact that this new conjugate vaccine works in pre-school children, right down to 9 months is a really big deal and important to be able to tackle typhoid across the board in all the children who suffer with it,” she said.

Gordon also said the vaccine efficacy data provides hope that sub-Saharan Africa can be rid of the multidrug-resistant strain of typhoid that arrived from Asia about a decade ago.

“In Malawi, the incidents are something [around] four or five hundred cases per 100,000 per year. Now anything over 200 is considered high incidence, so we are a very high-incidence country. There have been studies in Burkina Faso, in Ghana, in Kenya; we know that many other African countries have an equivalent burden of the disease,” Gordon said.

Dr. Queen Dube, chief of health services in Malawi’s Health Ministry, says rollout should begin soon.

“The exciting news is that we had applied to GAVI that supports us on the vaccination front to add this to the list of vaccines we are administering in the country and GAVI approved our application. And we are looking at introducing this typhoid vaccine and rolling it out next year,” Dube said.

However, some fear the new typhoid vaccine would face hesitancy and resistance from people, as has been the case with COVID-19 vaccines, and which led to the incineration of about 20,000 expired doses in Malawi in May.

But Dube said this won’t happen with typhoid vaccine because COVID-19 was a new disease.

“We have had typhoid for decades and decades, so people know what typhoid is. Nobody will wake up in the morning saying, oh no, typhoid was manufactured in a laboratory. And so, chances that you will end up with misinformation are on the lower side compared with a new disease which swept across the globe, killing so many people brought a lot of fear and a allowed a lot of false theories,” she said.

Still, Dube said Malawi’s government plans to launch a massive sensitization campaign to teach people about the new typhoid vaccine to a reemergence of the myths and misinformation that engulfed the COVID-19 vaccine rollout.

Source: Voice of America

Space Tourists Splash Down in Atlantic, End 3-Day Trip

Four space tourists ended their trailblazing trip to orbit Saturday with a splashdown in the Atlantic off the Florida coast.

Their SpaceX capsule parachuted into the ocean just before sunset, not far from where their chartered flight began three days earlier.

The all-amateur crew was the first to circle the world without a professional astronaut.

The billionaire who paid undisclosed millions for the trip and his three guests wanted to show that ordinary people could blast into orbit by themselves, and SpaceX founder Elon Musk took them on as the company’s first rocket-riding tourists.

SpaceX’s fully automated Dragon capsule reached an unusually high altitude of 585 kilometers (363 miles) after Wednesday night’s liftoff. Surpassing the International Space Station by 160 kilometers (100 miles), the passengers savored views of Earth through a big bubble-shaped window added to the top of the capsule.

Rare return to Atlantic

The four streaked back through the atmosphere early Saturday evening, the first space travelers to end their flight in the Atlantic since Apollo 9 in 1969. SpaceX’s two previous crew splashdowns — carrying astronauts for NASA — were in the Gulf of Mexico.

This time, NASA was little more than an encouraging bystander, its only tie being the Kennedy Space Center launch pad once used for the Apollo moonshots and shuttle crews, but now leased by SpaceX.

The trip’s sponsor, Jared Isaacman, 38, an entrepreneur and accomplished pilot, aimed to raise $200 million for St. Jude Children’s Research Hospital. Donating $100 million himself, he held a lottery for one of the four seats. He also held a competition for clients of his Allentown, Pennsylvania, payment-processing business, Shift4 Payments.

Joining him on the flight were Hayley Arceneaux, 29, a St. Jude physician assistant who was treated at the Memphis, Tennessee, hospital nearly two decades ago for bone cancer, and contest winners Chris Sembroski, 42, a data engineer in Everett, Washington, and Sian Proctor, 51, a community college educator, scientist and artist from Tempe, Arizona.

Strangers until March, they spent six months training and preparing for potential emergencies during the flight, dubbed Inspiration4. Most everything appeared to go well, leaving them time to chat with St. Jude patients, conduct medical tests on themselves, ring the closing bell for the New York Stock Exchange, and do some drawing and ukulele playing.

Arceneaux, the youngest American in space and the first with a prosthesis, assured her patients, “I was a little girl going through cancer treatment just like a lot of you, and if I can do this, you can do this.”

They also took calls from Tom Cruise, interested in his own SpaceX flight to the space station for filming, and the rock band U2’s Bono.

Atypical menu

Even their space menu wasn’t typical: cold pizza and sandwiches, but also pasta Bolognese and Mediterranean lamb.

Nearly 600 people have reached space — a scorecard that began 60 years ago and is expected to soon skyrocket as space tourism heats up.

Benji Reed, a SpaceX director, anticipates as many as six private flights a year, sandwiched between astronaut launches for NASA. Four SpaceX flights are already booked carry paying customers to the space station, accompanied by former NASA astronauts. The first is targeted for early next year with three businessmen paying $55 million apiece. Russia also plans to take up an actor and film director for filming next month and a Japanese tycoon in December.

Customers interested in quick space trips are turning to Richard Branson’s Virgin Galactic and Jeff Bezos’ Blue Origin. The two rode their own rockets to the fringes of space in July to spur ticket sales; their flights lasted 10 to 15 minutes.

Source: Voice of America

China’s COVID-19 Vaccine Diplomacy Reaches 100-Plus Countries

Despite doubts about the effectiveness of China’s COVID-19 vaccines, the global vaccine shortage is giving China an international soft power boost.

China’s Ministry of Foreign Affairs announced this week via the official Xinhua News Agency that it had delivered 1.1 billion vaccine doses to more than 100 countries during the pandemic.

This component of Chinese soft power, a tool used to deepen friendships abroad and vie for recognition over its archrival, the United States, despite festering disputes, could help boost China’s image in vaccine-recipient countries that cannot easily source doses from other places, observers said

“They work, maybe, less effectively and efficiently and timely than the vaccines that are produced in the Western countries but nonetheless they offer a certain level of immunization that’s always better than no immunization at all,” said Fabrizio Bozzato, senior research fellow at the Tokyo-based Sasakawa Peace Foundation’s Ocean Policy Research Institute.

“It appears that China’s vaccine diplomacy is working very well, to the detriment of the West, given the impression that it’s keeping the best weapons against COVID-19 to themselves,” Bozzato said. China will enjoy an image as a “reliable partner that’s willing to help,” he said.

Limited effectiveness, widespread availability

Of the vaccines developed in China, the World Health Organization calls Sinovac doses 51% effective against symptomatic infections and Sinopharm vaccine 79% effective. Specific data points, especially on the effectiveness against the delta variant, are few, said John Swartzberg, a clinical professor emeritus at the University of California-Berkeley’s School of Public Health. However, Chinese formulas work better than no vaccine, he said.

Within the year, China plans to offer a cumulative 2 billion vaccine doses abroad “and this can totally be done,” Xinhua says. Southeast Asia alone has received 360 million doses to date, it adds.

Xinhua says China has established vaccine plants in 15 countries, a boon to low-cost distribution. Sinovac was one of the world’s first pharmaceutical firms to develop a mass-market vaccine last year.

The United States is accelerating plans to distribute more vaccines. In June, the U.S. purchased 500 million doses to be distributed by COVAX, the WHO-backed initiative for low and middle-income countries. As of August, the U.S. government had donated 110 million doses overseas.

But that has done little to satisfy critics such as New York-based advocacy group Amnesty international, who say Western countries are “hoarding” vaccines for their own populations.

In a June statement, the group criticized the bilateral purchase agreements between wealthy countries and pharmaceutical companies, saying “instead of facing up to their international obligations by waiving intellectual property rules for vaccines, tests and treatments, and sharing lifesaving technology, G-7 leaders have opted for more of the same paltry half-measures.”

Media reports say President Joe Biden is expected to announce plans next week at the U.N. General Assembly for countries to pledge resources to vaccinate 70% of the world by September 2022. According to the World Health Organization, that will require about 11 billion doses.

And that effort could still run into supply bottlenecks.

Pfizer, a top name in the United States, points to obstacles offshore in vaccine packing, distribution and cold storage, but company CEO Albert Bourla said in an open letter that Pfizer is “continuing to work around the clock so we can bring the vaccine to the world as quickly, efficiently and equitably as possible.”

Many people in poorer parts of the world where COVID-19 cases continue to multiply are getting the Chinese shots with few side effects and a sense that any breakthrough infections would be mild, according to analysts and people from affected countries.

“History’s not going to look very kindly on China’s reluctance to be more forthcoming with their data, but history may be pretty kind to China if China just produces a lot of this vaccine and makes it available worldwide,” Swartzberg said.

Some Indonesians can choose only between a Chinese vaccine or none, said Paramitaningrum, an international relations lecturer at Bina Nusantara University in Jakarta. She and her aging parents got the Chinese vaccines earlier in the year.

China’s image isn’t getting worse, Paramitaningrum said. “That kind of anti-Chinese sentiment is still there, but I could say it has low percentage – only for some particular reasons – but in general they are OK,” she said.

Vaccines not expected to cure old disputes

In some countries, China’s vaccine diplomacy is not enough to erase pre-existing disputes.

Indonesians and Filipinos resent Chinese expansion in the 3.5 million-square-kilometer South China Sea where maritime sovereignty claims overlap. China, backed by Asia’s strongest military, has built artificial islands on shoals and reefs that Manila claims. Chinese ships also sail through waters that Jakarta says fall within its exclusive economic zone.

Other countries are embroiled in trade and investment flaps with China while people in much of the world bristle toward China as the coronavirus’s source.

The widespread availability of low-cost or donated Chinese medical aid won’t neutralize those issues but could temper any new flare-ups, analysts believe.

Most vaccines introduced in Brazil earlier this year came from Sinovac, and Brazilian researchers said in December after a clinical trial that the vaccine was more than 50% effective.

Still, Brazilian President Jair Bolsonaro said May 5 that the pandemic could be “chemical warfare” waged by a fast-growing nation widely presumed to mean China.

But heads of state in the Philippines and Vietnam, another normally outspoken South China Sea claimant, have not engaged in anti-China comments.

Common Filipinos take a pragmatic through guarded view. Many prefer non-Chinese vaccines but cannot tell clinics which brand to administer, domestic news website Inquirer.net reports.

“The president, the executive of the country, it’s his decision to bring in Sinovac, but on the ground the people, that’s really their last choice,” said Marivic Arcega, operator of an animal feed distributor in the Manila suburb of Cavite. She got an AstraZeneca shot while her husband got Sinovac.

In Vietnam, which began accepting Chinese vaccines in June, a lot of people are refusing the shots despite their country’s first major COVID-19 outbreak that began in June, said Jack Nguyen, partner at the business advisory firm Mazars in Ho Chi Minh City.

Source: Voice of America